Strategic Optimization of the product line Noor and Nord actively suspended two new drug development projects in the study of obesity.

Recently, Noor and Nord released Q2 performance report shows that the company terminated the development of two new drug research projects, involving a glutatrogin/GLP-1 receptor co-excitement and a GLP-1, gastric inhibitor peptides and glutatrogin receptor triple complete atriater, both of which are obese.
Over the past two years, Noor and NORD have expanded their product range for chronic disease treatments by working with leading companies in cardiovascular disease, non-alcoholic fatty hepatitis, chronic kidney disease, and innovative therapies.
it's worth noting that the development of two new drugs to actively end obesity is not a clinical failure, but rather a positive result for the other two drugs in obesity research.
and Nordga code layout of the new drug line for obesity treatment in the field of sugar-lowering drugs, Noor and NORD have been exploring for more than 30 years, dedicated to the development of safe and effective GLP-1 subject astrogen products.
At the end of December 2014, norovirus's diabetes drug liraglutide was approved by the FDA for adult obese patients with bMI of 30 kg m-2 or BMI of 27 kg m-2, and obesity-related complications such as diabetes or high blood pressure.
in the GLP-1 field, its long-acting product Division Meglutide has demonstrated excellent sugar and weight loss efficacy in previous studies.
the drug helps people eat less and reduce their calorie intake by reducing hunger and satiety.
and Nord are studying the use of the weekly smeglutide 2.4 mg for the treatment of adult obese patients.
addition to GLP-1, Noor and Nord are studying the use of AM833 for weight management in patients with at least one weight-related combination associated with obesity and overweight.
AM833 is a long-acting similar to human tryptopylization that reduces body weight by reducing energy intake.
this time, Noor and Nord have voluntarily terminated the development of two new drugs for obesity, based primarily on two positive clinical outcomes associated with AM833 for obesity treatment.
in particular, clinical research data used by AM833 in association with Smegropeptide further strengthen norovirus's obesity product line and have the potential to fill the gap between drug therapy and obesity surgery.
and Nord are actively terminating new drug development projects, pooling their resources and pushing the listing of Smegropeptide and AM833 in the field of obesity treatment.
AM833 Two clinical studies on June 18, Noor and Nord announced the main results of two clinical trials of a new type of serotonin-like AM833 that is injected once a week, namely, a single-drug treatment of phase II. clinical studies and a phase I clinical study of Smeglutide 2.4 mg, which is injected once a week under the skin.
AM833 single-drug treatment Phase II clinical study included 706 patients who were obese or overweight with at least one weight-related combination for 26 weeks and set up five different week dose groups to observe the safety, tolerance and effectiveness of AM833 for weight management.
The study reached its main clinical endpoint, losing 10.8 percent of their weight at 26 weeks compared to the average baseline weight of 107.4 kg, while patients in the placebo group lost 3.0 percent, the difference in treatment was statistically significant, and am833 was safe and well-to-do.
AM833 Joint Smegropeptide I. phase clinical study included 80 obese or overweight patients for 20 weeks to observe the safety, tolerance, pharmacodynamic properties and weight loss potential of AM833 in association with Smeglutide 2.4 mg.
the trial, the average baseline weight of the subjects who received the highest dose was 95.5 kg, and the average weight loss after 20 weeks of treatment was 17.1%.
the potential therapeutic market for obesity treatment drugs Obesity is a chronic metabolic disease caused by a variety of factors, characterized by an increase in the volume and number of cells in the body, accompanied by a variety of complications.
chronic disease requires long-term treatment and can be accompanied by many serious health consequences and reduced life expectancy.
the world, several drugs approved for obesity treatment, such as aphdamines and sibuqueramine, have been withdrawn due to serious side effects.
so far, the only drug approved on the Chinese market for obesity treatment is Olysser, a gastrointestinal and pancreatic lipase inhibitor with sales of 300 million yuan in 2018.
it is important to note that obesity is becoming a growing problem, with nearly 700 million people worldwide obese by the end of 2019 and the vast majority of patients not being treated with effective medication, an area that is in great demand.
focus on the Chinese market, in similar areas of drugs, domestic pharmaceutical companies have also launched the development of new drugs for obesity treatment.
At the end of October 2019, the recombinant anti-human GLP-1 humanized monoclonal antibody injection Grota pearl monoantigen injection developed by local pharmaceutical company Hongyun Fanning was approved for clinical trials of overweight or obesity in adults.
has a half-life of more than a week, early clinical trials in Australia have shown good safety and are expected to develop weight-loss drugs that are given once a week.
.